Filing Flows › Ultragenyx Pharmaceutical (RARE) › Product revenue
Ultragenyx Pharmaceutical (RARE) Product revenue by quarter
Ultragenyx Pharmaceutical's Product revenue was $105M in Q3 2026 (third quarter 2026), -6% from Q2 2026. Over the last 7 quarters it ranged from $80.8M (Q2 2025) to $112M (Q2 2026).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $105M | -6% | +11% |
| Q2 2026 | $112M | +26% | +39% |
| Q1 2026 | $89.0M | -12% | -3% |
| Q4 2025 | $102M | +7% | — |
| Q3 2025 | $95.0M | +18% | — |
| Q2 2025 | $80.8M | -12% | — |
| Q1 2025 | $91.5M | — | — |
Q3 2026 at a glance
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ultragenyx Pharmaceutical's Product revenue?
Ultragenyx Pharmaceutical's Product revenue was $105M in Q3 2026 (third quarter 2026), -6% from Q2 2026.
How has Ultragenyx Pharmaceutical's Product revenue changed?
Over the last 7 quarters it ranged from $80.8M (Q2 2025) to $112M (Q2 2026).
Q3 2026 results → · How Ultragenyx Pharmaceutical makes money →